Lv4
732 积分 2023-04-11 加入
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
22小时前
已完结
The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment
23小时前
已完结
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
4天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
4天前
已完结
Prognostic and predictive biomarkers in non-small cell lung carcinoma
5天前
已完结
NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China
5天前
已完结
A questionnaire survey to explore the current treatment policies adopted for patients with advanced hepatocellular carcinoma at board‐certified HPB training institutions in Japan: A JSHBPS project study 2023, Part 1
10天前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
16天前
已完结
Efficacy and Safety of Sunvozertinib Monotherapy as First-line Treatment in NSCLC Patients with EGFR Exon 20 Insertion Mutations: A Phase 2, Single-center Trial
19天前
已关闭
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
23天前
已完结
皖公网安备34019202002308
